JFS Wealth Advisors’s Ligand Pharmaceuticals LGND Stock Holding History

JFS Wealth Advisors’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.85K	Buy	9 +6	+200%	+$1.41K	﹤0.01%	1488
2026 Q1	$599	Hold	3	–	–	﹤0.01%	1752
2025 Q4	$568	Buy	+3	New	+$576	﹤0.01%	1784
2023 Q3	–	Sell	-5	Closed	-$361	–	1987
2023 Q2	$361	Buy	5 +2	+67%	+$150	﹤0.01%	1802
2023 Q1	$221	Hold	3	–	–	﹤0.01%	1814
2022 Q4	$200	Sell	3 -2	-40%	-$130	﹤0.01%	1828
2022 Q3	$0	Buy	5 +2	+67%	+$118	﹤0.01%	1837
2022 Q2	$0	Sell	3 -5	-63%	-$284	﹤0.01%	1850
2022 Q1	$1K	Buy	8 +5	+167%	+$363	﹤0.01%	1674
2021 Q4	$0	Buy	+3	New	+$277	﹤0.01%	1810

Other funds holding LGND

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

MAP

Moody Aldrich Partners Marblehead, Massachusetts $557M AUM 122.79% 1-Year Est. Return

Woodstock Corp Boston, Massachusetts $1.2B AUM 26.37% 1-Year Est. Return

MNBTD

Moody National Bank Trust Division Galveston, Texas $1.21B AUM 38.93% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

LTAS

Linden Thomas Advisory Services Charlotte, North Carolina $1.24B AUM 47.37% 1-Year Est. Return

TAM

Tealwood Asset Management Minneapolis, Minnesota $261M AUM 52.68% 1-Year Est. Return

YCM

Yousif Capital Management Bloomfield Hills, Michigan $8.94B AUM 42.6% 1-Year Est. Return

PWG

Portside Wealth Group Provo, Utah $858M AUM 26.82% 1-Year Est. Return

COPPSERS

Commonwealth of Pennsylvania Public School Employees Retirement System Harrisburg, Pennsylvania $20.6B AUM 37.37% 1-Year Est. Return

JFS Wealth Advisors's LGND Position: Q2 2026 in Review

JFS Wealth Advisors increased its Ligand Pharmaceuticals (LGND) stake by 200% in Q2 2026, buying an estimated $1.41K and bringing the position to 9 shares worth $2.85K. The position accounts for ﹤0.01% of the portfolio, ranked #1488.

JFS Wealth Advisors first reported a position in LGND in Q4 2021 and has held it in 10 quarters since. 36 funds tracked by Wall St. Rank hold LGND as of Q2 2026.

JFS Wealth Advisors held 9 shares of Ligand Pharmaceuticals worth $2.85K as of Q2 2026.
JFS Wealth Advisors bought 6 Ligand Pharmaceuticals shares in Q2 2026, an estimated $1.41K.
Ligand Pharmaceuticals made up ﹤0.01% of JFS Wealth Advisors's portfolio in Q2 2026, its #1488 holding.
JFS Wealth Advisors first reported a position in Ligand Pharmaceuticals in Q4 2021 and has held it in 10 quarters since.
36 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2026.

Based on JFS Wealth Advisors's 13F filing for Q2 2026, filed 10 Jul 2026.